(19)
(11) EP 4 823 572 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24829085.0

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
A61K 31/438(2006.01)
A61P 9/12(2006.01)
A61K 31/7042(2006.01)
 A61K 31/7032(2006.01)
A61P 13/12(2006.01)
A61K 31/7048(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/438; A61P 9/12; A61P 13/12; A61K 31/7048; A61K 31/7042
 
C-Sets:
  1. A61K 31/438, A61K 2300/00;
  2. A61K 31/7042, A61K 2300/00;
(86) International application number:
PCT/EP2024/086083
(87) International publication number:
WO 2025/125513 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 15.12.2023 US 202363610570 P

(71) Applicant: AstraZeneca Ireland Limited
Dublin 15, D15 R925 (IE)

(72) Inventors:
  • LITTLE, Dustin
    Wilmington, Delaware 19850-5437 (US)
  • ROSSERT, Jerome
    Wilmington, Delaware 19850-5437 (US)
  • MYTE, Robin
    151 85 Södertälje (SE)

(74) Representative: AstraZeneca Intellectual Property 
Eastbrook House Shaftesbury Road
Cambridge CB2 8BF
Cambridge CB2 8BF (GB)

   


(54) SGLT2 INHIBITORS AND BAXDROSTAT FOR TREATING CHRONIC KIDNEY DISEASE AND HYPERTENSION